These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8627566)

  • 1. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
    Kudlacz EM; Shatzer SA; Knippenberg RW; Logan DE; Poirot M; van Giersbergen PL; Burkholder TP
    J Pharmacol Exp Ther; 1996 May; 277(2):840-51. PubMed ID: 8627566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The peripheral NK-1/NK-2 receptor antagonist MDL 105,172A inhibits tachykinin-mediated respiratory effects in guinea-pigs.
    Kudlacz EM; Knippenberg RW; Shatzer SA; Kehne JH; McCloskey TC; Burkholder TP
    J Auton Pharmacol; 1997 Apr; 17(2):109-19. PubMed ID: 9234081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of MDL 105,212, a nonpeptide NK-1/NK-2 receptor antagonist in an allergic guinea pig model.
    Kudlacz EM; Knippenberg RW; Logan DE; Burkholder TP
    J Pharmacol Exp Ther; 1996 Nov; 279(2):732-9. PubMed ID: 8930178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
    Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
    Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.
    Gitter BD; Bruns RF; Howbert JJ; Waters DC; Threlkeld PG; Cox LM; Nixon JA; Lobb KL; Mason NR; Stengel PW
    J Pharmacol Exp Ther; 1995 Nov; 275(2):737-44. PubMed ID: 7473161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs.
    Tsuchida H; Takahashi S; Nosaka E; Kuraya T; Yamashita M; Morimoto K
    Eur J Pharmacol; 2008 Oct; 596(1-3):153-9. PubMed ID: 18706408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of selective antagonists for further characterization of tachykinin NK-2, NK-1 and possible "septide-selective" receptors in guinea pig bronchus.
    Zeng XP; Burcher E
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1295-300. PubMed ID: 7523658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
    Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
    Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for adrenergic and tachykinin activity in venom of the stonefish (Synanceja trachynis).
    Hopkins BJ; Hodgson WC; Sutherland SK
    Toxicon; 1996 May; 34(5):541-54. PubMed ID: 8783449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
    Anthes JC; Chapman RW; Richard C; Eckel S; Corboz M; Hey JA; Fernandez X; Greenfeder S; McLeod R; Sehring S; Rizzo C; Crawley Y; Shih NY; Piwinski J; Reichard G; Ting P; Carruthers N; Cuss FM; Billah M; Kreutner W; Egan RW
    Eur J Pharmacol; 2002 Aug; 450(2):191-202. PubMed ID: 12206858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of nitric oxide and septide-insensitive NK(1) receptors in bronchoconstriction induced by aerosolised neurokinin A in guinea-pigs.
    Ricciardolo FL; Trevisani M; Geppetti P; Nadel JA; Amadesi S; Bertrand C
    Br J Pharmacol; 2000 Mar; 129(5):915-20. PubMed ID: 10696090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor.
    McLean S; Ganong A; Seymour PA; Snider RM; Desai MC; Rosen T; Bryce DK; Longo KP; Reynolds LS; Robinson G
    J Pharmacol Exp Ther; 1993 Oct; 267(1):472-9. PubMed ID: 7693914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of FK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerve stimulation in guinea pigs.
    Murai M; Morimoto H; Maeda Y; Kiyotoh S; Nishikawa M; Fujii T
    J Pharmacol Exp Ther; 1992 Jul; 262(1):403-8. PubMed ID: 1378097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics.
    Joos GF; Van Schoor J; Kips JC; Pauwels RA
    Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1781-4. PubMed ID: 8665034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
    Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
    J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
    Juszczak M; Boczek-Leszczyk E; Stempniak B
    J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist.
    Gerspacher M; Lewis C; Ball HA; Howes C; Subramanian N; Ryffel K; Fozard JR
    J Med Chem; 2003 Jul; 46(16):3508-13. PubMed ID: 12877589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.